Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration

MAPS Public Benefit Corporation (MAPS PBC) announced today that it has selected the contract research organisation (CRO), MMS Holdings (MMS), as its CRO for the development of a New Drug Application (NDA) for MDMA-assisted therapy for PTSD. MMS will support the NDA submission by providing regulatory strategy, biostatistics, statistical programming, medical writing, medical review, publishing, and submission project management support.